A novel design using a virtual control group to evaluate non-inferiority of nevirapine and lamivudine dual maintenance in HIV therapy
Alessandro Suter, Markus Bickel, Carsten Depmeier, Peter Gute, Gaby Knecht, Marcel Stöckle, Christoph Fux, Baharak Babouee Flury · 2026
Read A novel design using a virtual control group to evaluate non-inferiority of nevirapine and lamivudine dual maintenance in HIV therapy by Alessandro Suter, Markus Bickel, Carsten Depmeier, Peter Gute, Gaby Knecht, Marcel Stöckle, Christoph Fux, Baharak Babouee Flury (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0351576.txt.
Description
Alessandro Suter and seven colleagues report this 2026 PLOS One trial of a simpler two-drug maintenance treatment for people living with HIV. Participants had already kept the virus suppressed for at least two years on standard combined therapy. The study switched them to just nevirapine and lamivudine for forty-eight weeks and compared their results against a simulated control group assumed to have no treatment failures.
About two hundred patients at five centers in Switzerland and Germany took part, and nearly all finished the study. Only two had confirmed viral rebound, both tied to missed doses, and none failed during a further year of follow-up. The authors say the two-drug regimen held up as well as the ideal control, while noting the result applies only to patients who meet the study's strict entry rules.
Catalog record
| CREATOR | Alessandro Suter, Markus Bickel, Carsten Depmeier, Peter Gute, Gaby Knecht, Marcel Stöckle, Christoph Fux, Baharak Babouee Flury |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31791 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |